IFNA2 and neoplasm: While IFNα2 and other type I interferons showed promising anti-tumor effects, it soon became clear that systemic administration was associated with severe adverse outcomes, including cytopenias, fatigue, anorexia, hepatotoxicity, flu-like symptoms and severe depression with suicidal ideation[56,57].